Welcome to our dedicated page for Aclaris Therapeutics news (Ticker: ACRS), a resource for investors and traders seeking the latest updates and insights on Aclaris Therapeutics stock.
Aclaris Therapeutics Inc (NASDAQ: ACRS) is a clinical-stage biopharmaceutical leader focused on pioneering therapies for immuno-inflammatory and dermatologic diseases. This page serves as the definitive source for verified news and press releases related to ACRS's research advancements, strategic partnerships, and operational developments.
Investors and industry professionals will find timely updates on clinical trial progress, regulatory milestones, and financial announcements. The curated collection includes updates on novel drug candidates like kinase inhibitors and antibody therapies targeting conditions with significant unmet medical needs.
All content is organized to provide clear insights into ACRS's dual-segment operations – from therapeutic innovations to contract research services. Regular updates ensure stakeholders stay informed about licensing agreements, pipeline expansions, and scientific breakthroughs without promotional bias.
Bookmark this page for streamlined access to essential Aclaris Therapeutics updates. Check back frequently for authoritative reporting on developments impacting both clinical research and investment considerations in the biopharmaceutical sector.
Aclaris Therapeutics (NASDAQ: ACRS) has received FDA clearance for its Investigational New Drug (IND) application to conduct a Phase 1a/1b clinical trial of ATI-052, a bispecific anti-TSLP/IL-4R monoclonal antibody. The trial, expected to begin in Q2 2025, will evaluate single and multiple ascending doses followed by a proof-of-concept portion in an undisclosed indication.
ATI-052, acquired through a license agreement with Biosion, is designed to exhibit high binding affinity and dual blockade of both the TSLP ligand and IL-4 receptor, inhibiting key proinflammatory pathways. This bispecific antibody technology represents a potential advancement in immunotherapy, as these engineered antibodies can bind to two targets simultaneously, potentially offering enhanced efficacy over traditional monoclonal antibodies.
Aclaris Therapeutics (NASDAQ: ACRS), a clinical-stage biopharmaceutical company specializing in immuno-inflammatory diseases, has announced its participation in two major healthcare conferences this March.
The company's leadership team, led by CEO Dr. Neal Walker, will engage in:
- A fireside chat at the Leerink Partners Global Healthcare Conference in Miami, Florida on March 11, 2025, at 3:00 PM EDT
- A virtual fireside chat during the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference on March 27, 2025, at 9:00 AM EDT
Both events will be webcast live and archived on the Events page of Aclaris' website, remaining accessible for at least 30 days following the presentations.
Aclaris Therapeutics (NASDAQ: ACRS) reported its Q4 and full-year 2024 financial results, highlighting multiple clinical catalysts expected in 2025. The company ended 2024 with $203.9 million in cash and equivalents, extending runway into 2028.
Key financial metrics include a Q4 net loss of $96.6 million compared to $1.5 million in Q4 2023, and total revenue of $9.2 million versus $17.6 million in the prior year period. R&D expenses decreased to $9.0 million from $26.6 million year-over-year.
Notable developments include:
- Acquisition of worldwide rights (excluding Greater China) to bosakitug (ATI-045) and ATI-052 from Biosion
- Expected Phase 2 data from CTTQ's studies in severe asthma and CRSwNP in H1 2025
- Planned initiation of Phase 2b trial for bosakitug in atopic dermatitis in H1 2025
- Completion of $80 million private placement in November 2024
Aclaris Therapeutics (NASDAQ: ACRS) announced a new publication highlighting the properties of ATI-2138, their novel investigational covalent inhibitor of ITK and JAK3 for treating autoimmune and inflammatory diseases. The drug demonstrates potent and selective blocking of both ITK and JAK3, effectively inhibiting key T cells involved in conditions like atopic dermatitis, alopecia areata, and vitiligo.
The publication details ATI-2138's performance in biochemical target inhibition, cellular systems, and animal models. Key findings show the drug's unique pharmacological profile with high potency in inhibiting both ITK and JAK3. In initial clinical trials, ATI-2138 was generally well-tolerated, with no serious adverse events reported. The drug showed dose- and time-dependent modulation of biomarkers linked to both ITK and JAK3 activity in healthy participants.
Aclaris Therapeutics (NASDAQ: ACRS) has announced the formation of a new Scientific Advisory Board (SAB) focused on pulmonology expertise. The initial board includes two distinguished members: Dr. Marianne Mann, a pulmonologist with over 30 years of experience in regulatory science and former FDA Deputy Director, and Dr. Zuzana Diamant, a renowned pulmonologist and clinical pharmacologist.
Dr. Mann brings extensive experience in clinical trial design and regulatory strategy from her roles at the FDA and NIH. Dr. Diamant, a guest professor at KU Leuven and past-chair of multiple respiratory medicine organizations, has co-authored over 200 peer-reviewed publications and brings expertise in drug development and clinical studies for respiratory diseases.
The SAB will guide Aclaris's development programs for immuno-inflammatory diseases, leveraging the members' combined expertise in respiratory medicine, clinical pharmacology, and immunology.
Aclaris Therapeutics (NASDAQ: ACRS) has announced inducement grants under NASDAQ Listing Rule 5635(c)(4). The company's Compensation Committee granted 215,000 nonstatutory stock options and 61,000 restricted stock units to one new employee under their 2024 Inducement Plan.
The stock options have an exercise price of $2.48 per share, matching Aclaris' common stock closing price on January 2, 2025. Both the options and restricted stock units will vest in four equal annual installments of 25% each, starting from the grant date, contingent on continued employment. These equity awards were granted as material inducements for the new employee joining Aclaris, in compliance with NASDAQ rules.
Aclaris Therapeutics (NASDAQ: ACRS) announced new employee equity grants under its 2024 Inducement Plan. The company granted nonstatutory stock options to purchase 251,000 shares and 73,000 restricted stock units to 4 new employees. Additionally, Hugh Davis, Ph.D, the new President and Chief Operating Officer, received options to purchase 375,000 shares and 107,000 restricted stock units.
The options have an exercise price of $3.96 per share, matching the closing price on December 2, 2024. Both options and restricted stock units will vest 25% annually over four years, contingent on continued employment. These grants were made as employment inducements in accordance with NASDAQ Listing Rule 5635(c)(4).
Aclaris Therapeutics (NASDAQ: ACRS), a clinical-stage biopharmaceutical company specializing in immuno-inflammatory disease treatments, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The company's management team will engage in a fireside chat on Tuesday, December 3, 2024, at 1:00 PM ET in New York.
Interested parties can access the webcast through the 'Events' page in the 'Investors' section of Aclaris' website. The recording will remain available for a minimum of 30 days on www.aclaristx.com.
Biosion has entered into an exclusive license agreement with Aclaris Therapeutics (NASDAQ: ACRS) for worldwide rights (excluding Greater China) to two immunology assets: BSI-045B and BSI-502. The deal includes an upfront payment of over $40 million, 19.9% of Aclaris common stock, and potential milestone payments exceeding $900M with tiered royalties.
BSI-045B, a clinical-stage anti-TSLP antibody, has shown promising results in a Phase 2a trial for atopic dermatitis with 22 patients. BSI-502 is a pre-clinical stage bispecific antibody targeting both TSLP and IL4R. The agreement grants Aclaris development and commercialization rights worldwide, except for Greater China.
Aclaris Therapeutics (NASDAQ: ACRS) has secured an exclusive global license agreement with Biosion for worldwide rights (excluding Greater China) to two key biologics: BSI-045B, a clinical-stage anti-TSLP monoclonal antibody, and BSI-502, a pre-clinical stage bispecific antibody targeting TSLP and IL4R. BSI-045B has shown promising results in a Phase 2a trial for atopic dermatitis with 22 patients. The company also announced the appointment of two new executives: Hugh Davis as President and COO, and Steven Knapp as EVP, Head of Regulatory & Quality. The agreement strengthens Aclaris' pipeline in immunology with both small and large molecule drugs.
